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Abstract 
Background: The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal 
cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid 
Tumors (RECIST) with the Cytologic Criteria Assessing Response (CyCAR), based on the presence and phenotypic 
characterization of CTCs, as indicators of FOLFOX–bevacizumab treatment response.
Methods: 77 mCRC blood samples from FOLFOX–bevacizumab treated patients were analyzed to isolate CTCs 
before and after (12 and 24 weeks) treatment, using an immunomagnetic separation method. VEGFR expression was 
identified by double immunostaining.
Results: We observed a decrease of CTCs (42.8 vs. 18.2%) and VEGFR positivity (69.7% vs. 41.7%) after treatment. 
According to RECIST, 6.45% of the patients did not show any clinical benefit, whereas 93.55% patients showed a 
favorable response at 12 weeks. According to CyCAR, 29% had a non‑favorable response and 71% patients did not. No 
significant differences were found between the response assessment by RECIST and CyCAR at 12 or 24 weeks. How‑
ever, in the multivariate analysis, RECIST at 12 weeks and CyCAR at 24 weeks were independent prognostic factors for 
OS (HR: 0.1, 95% CI 0.02–0.58 and HR: 0.35, 95% CI 0.12–0.99 respectively).
Conclusions: CyCAR results were comparable to RECIST in evaluating the response in mCRC and can be used as an 
alternative when the limitation of RECIST requires additional response analysis techniques.
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Background
In colorectal cancer (CRC), metastasis is the main 
cause of death [1]. Distant metastasis is identified in 
approximately 25% of patients at initial diagnosis, and 
half of CRC patients will develop it [2]. During this pro-
cess, circulating tumor cells (CTCs), detach from pri-
mary sites, enter the bloodstream and extravasate in 
distant organs. CTCs are now being studied in order to 
have a deeper understanding of the metastatic processes 
[3]. The phenotypic and genetic characterization of CTCs 
is especially important; as different subpopulations of 
CTCs can be detected in the blood of these patients [4]. 
These CTCs subclones can depict in real time the het-
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to elude therapies, and therefore, determining tumor 
response to treatment [5].
Metastatic colorectal cancer patients (mCRC) are 
currently subjected to a treatment regime combining 
chemotherapy with biological therapies. Bevacizumab, a 
monoclonal antibody inhibits the tyrosine kinase vascu-
lar endothelial growth factor A (VEGF-A) and blocks its 
transduction signal, through both VEGFR-1 and VEGFR-
2. VEGF-A is a potent pro-angiogenic growth factor 
that stimulates proliferation, migration, and survival of 
endothelial cells. As it is one of the more important pro-
teins expressed by tumor cells, VEGF is an important tar-
get of anticancer therapies. Cancer cells and tissues with 
high metabolic rates are characterized by hypoxia, which 
induces the transcription of VEGF protein [6]. Circulat-
ing VEGF binds with high affinity to VEGF receptors 
(VEGFR-1 and VEGFR-2) and its co-receptors neuropilin 
(NRP-1 and NRP-2), which are expressed on the surface 
of endothelial cells and play a critical role in the devel-
opment of angiogenesis, by stimulating recruitment and 
proliferation of endothelial cells [7]. Bevacizumab is an 
IgG1 recombinant humanized monoclonal antibody that 
acts by selectively binding to circulating VEGF-A, creat-
ing a large molecule that renders it unable to bind to its 
cell surface receptors, reducing microvascular growth of 
tumor blood vessels and limiting blood supply of nutri-
ents and oxygen to tumor tissues. In combination with 
intravenous 5-fluorouracil-based chemotherapy, it is 
indicated for first- or second-line treatment of patients 
with metastatic colorectal cancer. In combination with 
fluoropyrimidine–irinotecan- or fluoropyrimidine–oxali-
platin-based chemotherapy, it is indicated for second-line 
treatment of patients with metastatic colorectal cancer 
who have progressed on a first-line Bevacizumab con-
taining regimen [8, 9]. First line bevacizumab has been 
demonstrated to improve overall survival (OS), progres-
sion-free survival (PFS) and treatment response rate in 
mCRC [10]. Despite these improvements, most mCRC 
patients will die due to disease progression [11]. With 
this in mind, extensive biomarker programs have now 
been built into numerous clinical studies with bevaci-
zumab. However, predictive markers for bevacizumab 
treatment have yet to be validated [12].
In this clinical experimental work, we aimed to estab-
lish the predictive role of CTCs, and their expression of 
a treatment-associated marker (VEGFR), as response 
biomarkers to bevacizumab in mCRC patients, as well 
as their relationship with disease progression and death 
risk. Furthermore, we then compared the Response 
Evaluation Criteria in Solid Tumors (RECIST) version 
1.1 [13] with our proposed Cytologic Criteria Assess-
ing Response (CyCAR), based on CTC status, to deter-
mine their respective utility as predictive and prognostic 
assessments. Finally, we compared treatment responses 
of mCRC patients under FOLFOX–bevacizumab-con-
taining chemotherapy by both criteria.
Methods
Study design
We conducted a prospective longitudinal cohort study of 
77 patients with mCRC who underwent first-line treat-
ment with FOLFOX6  m (Oxaliplatin 85  mg/m2, Leu-
covorin 400  mg/m2, 5-FU 400  mg/m2 bolus and 5-FU 
2400 mg/m2 over 46 h) and bevacizumab (5 mg/kg) every 
2 weeks until disease progression, at the Department of 
Oncology, San Cecilio University Hospital in Granada 
(Spain), between April 2011 and November 2015. Con-
trol blood samples were drawn from 16 healthy volun-
teers with no history of malignant disease.
The study was conducted in accordance with the Decla-
ration of Helsinki and approved by the ethical Committee 
of the Hospital. Written informed consent was obtained 
from every cancer patient and healthy volunteer.
None of the patients had received any other type of 
biological treatment before inclusion in the study. Com-
puted tomography of the chest, abdomen and pelvis 
was performed at baseline, at 12 weeks, at 24 weeks and 
finally each 12  weeks until death. Image interpretation 
was performed using RECIST, to classify each disease as 
complete response, partial response, stable disease, or 
progressive disease. Patients who died before a follow-
up imaging study were classified as having progressive 
disease. According to patient response to the therapy, 
they were divided into two groups: those with favorable 
response, including patients who have achieved complete 
response, partial response or stable disease, and those 
with non-favorable response, including patients without 
clinical benefit (progressive disease or death).
Median follow-up time for all patients was 23.3 months 
(range 2–105 months). Clinical outcomes were evaluated 
in terms of PFS and OS. PFS was defined as the elapsed 
time from the start of the treatment to progression or 
death. OS was defined as the elapsed time from the start 
of the treatment to death.
Data was collected for the following variables: age, gen-
der, primary tumor location, metastasis surgery, primary 
tumor surgery, synchronous metastasis, K-RAS status, 
Basal CEA, Basal Ca 19.9, progression, survival, RECIST 
and CyCAR responses (Table 1).
CyCAR results were based on the status of CTCs dur-
ing the treatment (Fig.  1). Thus, a patient was classified 
as a responder (favorable response) if he was negative at 
baseline and continued negative for CTCs at 12  weeks. 
However, a patient was classified as a non-responder 
(non-favorable response) if he showed CTCs at 12 weeks. 
In the same way, the patient was classified as responder 
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Table 1 Clinicopathological characteristics of  the  patients according to  the  CyCAR criteria at  baseline status (CTC1) 
and VEGFR status
*: Statistically significant
CyCAR: Cytologic Criteria Assessing Response; CTC: circulating tumor cell; VEGFR: vascular endothelial growth factor receptor; RECIST: Response Evaluation Criteria in 
Solid Tumors; p: p value
CTC 1 CTC 1 VEGFR
N (%) − N (%) + p N (%) − N (%) + p
Age (years)
 < 55 15 (62.5%) 9 (37.5%) 0.622 3 (33.3%) 6 (66.7%) 1.00
 ≥ 55 29 (54.7%) 24 (45.3%) 7 (29.2%) 17 (70.8%)
Gender
 Male 30 (58.2%) 21 (41.2%) 0.808 9 (40.9%) 13 (59.1%) 0.144
 Female 14 (53.9%) 12 (46.1%) 2 (16.7%) 10 (83.3%)
Primary tumor location
 Colon 25 (54.4%) 21 (45.6%) 0.641 5 (23.8%) 16 (76.2%) 0.164
 Rectum 19 (61.3%) 12 (38.7%) 6 (46.2%) 7 (53.8%)
Metastasis surgery
 No 32 (57.1%) 24 (42.9%) 1.00 8 (32%) 17 (68%) 0.625
 Yes 12 (57.1%) 9 (42.9%) 3 (33.3%) 6 (66.7%)
Primary tumor surgery
 No 21 (75%) 7 (25%) 0.019* 4 (57.1%) 3 (42.9%) 0.132
 Yes 23 (46.9%) 26 (53.1%) 7 (25.9%) 20 (74.1%)
Synchronous metastasis
 No 3 (25%) 9 (75%) 0.024* 2 (22.2%) 7 (77.8%) 0.686
 Yes 41 (63.1%) 24 (36.9%) 8 (33.3%) 16 (66.7%)
K‑RAS
 Mutated 25 (69.4%) 11 (30.6%) 0.061 4 (36.4%) 7 (63.6%) 0.546
 Wild‑type 18 (46.2%) 21 (53.8%) 7 (31.8%) 22 (68.2%)
Basal CEA
 Standard 6 (40%) 9 (60%) 0.153 2 (20%) 8 (80%) 0.339
 High 37 (61.7%) 23 (38.3%) 8 (34.8%) 15 (65.2%)
Basal Ca 19.9
 Standard 19 (46.3%) 22 (53.7%) 0.034* 7 (31.8%) 15 (68.2%) 0.627
 High 23 (71.9%) 9 (28.1%) 3 (30%) 7 (70%)
Progression
 Yes 28 (53.8%) 24 (46.2%) 0.485 7 (29.2%) 17 (70.8%) 0.634
 No 9 (64.3%) 5 (35.7%) 2 (40%) 3 (60%)
Survival
 Yes 18 (60%) 12 (40%) 1.00 3 (25%) 9 (75%) 0.683
 No 22 (61.1%) 14 (38.9) 5 (35.7%) 9 (64.3%)
RECIST 12 weeks
 Favorable 31 (53.4%) 27 (46.6%) 0.402 7 (25.9%) 20 (74.1%) 0.557
 Adverse 3 (75%) 1 (25%) 0 (0%) 1 (100%)
RECIST 24 weeks
 Favorable 19 (52.8%) 17 (47.2%) 0.376 4 (23.5%) 13 (76.5%) 0.468
 Adverse 5 (38.5%) 8 (61.5%) 3 (37.5%) 5 (62.5%)
CyCAR 12 weeks
 Favorable 29 (65.9%) 15 (34.1%) 0.087 4 (26.7%) 11 (73.3%) 1.00
 Adverse 7 (38.9%) 11 (61.1%) 3 (27.3%) 8 (72.7%)
CyCAR 24 weeks
 Favorable 30 (55.6%) 24 (44.4%) 0.537 7 (29.2%) 17 (70.8%) 0.574
 Adverse 8 (66.7%) 4 (33.3%) 2 (50%) 2 (50%)
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if he was negative for CTCs at 24 weeks, but he was clas-
sified as non-responder if he showed CTCs at 24 weeks.
Isolation and enumeration of CTCs
Peripheral blood was collected for CTCs evaluation 
before the initiation of therapy (baseline) (CTC1) and 
subsequently at 12 (CTC2), and 24 (CTC3) weeks after 
initiating the treatment.
For CTCs enrichment and detection, 10 ml of periph-
eral blood was collected from each mCRC patient and 
processed according to the protocols based on immuno-
magnetic selection and established by our group [14].
Enumeration and characterisation of CTCs by CK 
and VEGFR expression
Samples containing  CTCsCK+ were characterized for 
VEGFR expression by double immunofluorescence (IF) 
following our standard protocols [14]. We also analyzed 
17 healthy blood donors and a colon cancer cell line 
(HT29) to test the performance of the assays.
Fluorescence microscopy
Cytospins were previously analyzed for the presence 
of CTCs under direct light microscope to identify red 
stained pan-CK cells. Then, samples were observed using 
a computerized fluorescence microscope Zeiss AXIO 
Imager. A1 to detect cells with intense VEGFR stain-
ing. VEGFR positive cells  (CTCsCK+VEGFR+) showed an 
intense blue fluorescence signal on the surface (Fig. 2).
Statistical analysis
CTCs were assessed as a continuous and a binary vari-
able (presence/absence). The cut-off limit for CTC 
status as positive was CTCs ≥ 1. The relationships 
between CTCs and other variables were ascertained 
using Fisher’s exact test. The Wilcoxon signed-rank test 
was used to compare CTCs measured at two different 
times and the Cochran’s Q test to compare presence of 
CTCs at three different times. The influence of clinico-
pathological variables on PFS and OS was measured by 
univariate and multivariate Cox Proportional-Hazards 
Regression. We applied the criterion of more than a 
10% change in the CTC coefficient estimate [15] for the 
selection of variables to be included in the multivariate 
model.
Results
The study was performed in 77 patients with meta-
static cancer of colon and rectum (59.7% and 40.3% 
respectively). The median age was 61  years and 51% of 
patients were men. Only 12 patients (15.6%) presented 
synchronous metastases while 65 (84.4%) presented 
metachronous metastases (metastases developed at 
least 12  months after the primary tumor) (Table  1). In 
this way, 59 (76.6%) patients developed liver metastasis, 
8 (10.4%) lung metastasis and the remaining 10 (13%) 
developed metastasis in other organs as bone, lymph 
nodes or adrenal glands. Nevertheless, no relation was 
found between levels or status of CTCs and a predisposi-
tion to metastasis between organs (p > 0.05).
Fig. 1 CyCAR criteria based on the status of CTCs along the treatment. Dark grey circles identify persistence of CTCs and are associated with 
non‑responders. Light grey circles identify absence of CTCs and are associated with responders. Numbers in each circle = N
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Dynamic fluctuation of CTCs during follow‑up 
and correlation with clinicopathological characteristics
CTCs were detected in 33 of 77 (42.8%) patients at 
CTC1, in 18 of 62 (29%) patients at CTC2 and finally, 
in 12 of 66 (18.2%) patients at CTC3 (blood samples of 
some patients were lost due principally to the death of 
the patients, except for two of them, which could not be 
analyzed due to sample analysis problems). According 
to the data, we observed a significant decrease in num-
ber of patients with CTCs along the follow-up (CTC1–
CTC3) (p = 0.015) and between extraction points CTC1 
vs. CTC2 (0.019) and CTC1 vs. CTC3 (0.003). This way, 
the mean number of CTCs varied from an initial 1.5 cells 
per 10  ml of peripheral blood [standard deviation (SD): 
1.5; range 0–8] at CTC1, 1.7 cells (SD: 8.1; range 0–64) at 
CTC2, to a reduced number of 0.5 (SD: 1.5; range 0–9) at 
CTC3 (Table 2).
Correlation between CTC1 presence,  CTC1VEGFR sta-
tus and clinic-pathological characteristics is summa-
rized in Table 1. The primary tumor resection showed a 
significant correlation with CTC1 presence (p = 0.019). 
26 of 49 (53.1%) patients who underwent primary tumor 
resection were CTC1+, while only 7 of 28 (25%) patients 
without primary tumor resection were CTC1. Despite 
finding higher percentage of CTC1+ patients with wild-
type K-RAS tumors than patients with mutated K-RAS 
tumors (54% vs. 31% respectively), there was no signifi-
cant correlation between them (p = 0.061). Lower levels 
of basal Ca 19.9 significantly correlated with CTC1 pres-
ence (p = 0.034). Therefore, 22 of 41 (53.7%) patients 
with standard levels of Ca 19.9 showed CTC1 presence 
but only 9 of 32 (28.1%) did it in the higher levels group 
(Table 1).
Dynamic fluctuation of CTCs according to VEGFR status 
and correlation with clinic‑pathological characteristics
At baseline status,  CTC1CK+VEGFR+ were detected in 
23 of 33 (69.7%) patients. At the second extraction, we 
found  CTC2CK+VEGFR+ in 7 of 18 (38.9%) patients, and 
finally, we found  CTC3CK+VEGFR+ in 5 of 12 (41.7%) 
Fig. 2 Image gallery after isolation, cytomorphological analysis and detection of cytokeratin‑positive tumor cells (CK+, red staining) and vascular 
endothelial growth factor expression (VEGFR, blue staining). Top row shows HT29 cell tumor line used as a positive control for VEGFR expression. 
Middle (patient 1) and bottom (patient 2) rows show an example of heterogeneous expression of VEGFR in two different patients: patient 1 shows 
positive VEGFR expression in a CTC and patient 2 shows negative VEGFR expression in another CTC. VEGFR‑specific immunofluorescence (IF) CTCs 
were determined with Alexa  Fluor® 350
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patients. The mean number of  CTC1CK+VEGFR+ was 
1.4 per 10 ml of peripheral blood (SD: 1.5; range 0–5), 
0.6  CTC2CK+VEGFR+ (SD: 1.05; range 0–3) and 0.5 
 CTC3CK+VEGFR+ (SD: 0.8; range 0–2) (Table  2). Dur-
ing follow-up, although it was not statistically signifi-
cant, we noted a decrease not only in the percentage 
of patients with CTC CK+VEGFR+, but also in the num-
ber of CTC CK+VEGFR+ detected per patient (Table  2). 
However, no significant correlation was found between 
 CTC1CK+VEGFR+ status and any clinic-pathological 
characteristics of the patients, including K-RAS status 
(Table 1).
We compared the previously described CyCAR 
results to RECIST, in order to evaluate the response at 
12 and 24 weeks. We evaluated responses in 62 patients 
at 12  weeks (Fig.  3). According to RECIST, 4 of the 
62 (6.45%) patients showed non-favorable responses, 
while 58 of the 62 (93.55%) patients showed a favorable 
response. The CyCAR (CTC2) responses showed simi-
lar results, with 18 of the 62 patients (29%) developing 
non-favorable responses and 44 of the 62 (71%) patients 
developing a favorable one. As a result, we found no 
significant differences between the assessment response 
by RECIST and CyCAR at 12 weeks (p > 0.05).
At 24  weeks, we evaluated responses in 65 patients. 
In this case, according to RECIST, 13 of the 65 (20%) 
patients showed non-favorable responses, while 52 of 
them (80%) showed a favorable response. On the other 
hand, regarding CyCAR evaluation (CTC3), 12 of the 
65 patients (18.5%) showed non-favorable responses 
while 53 of them (81.5%) showed a favorable response. 
In the same way, we found no significant differences 
between both assessment criteria (p > 0.05).
Correlation between RECIST and CyCAR based on CTCs 
VEGFR status to evaluate response to FOLFOX–
bevacizumab
CyCAR results based on VEGFR status in CTC2 and 
CTC3 was compared to RECIST evaluation at 12 and 
24  weeks. At the first response evaluation time point 
(12  weeks), 18 patients were analyzed, while at the 
second response re-evaluation (24  weeks), only 12 of 
the 18 patients remained CTC3+ and were analyzed 
(Table 2).
According to RECIST at 12  weeks, 17 of the 18 
(94.4%) patients showed favorable responses and only 
1 of these 18 patients (5.6%) developed a non-favorable 
response. Using CyCAR, 7 of the 18  CTC2CK+ patients 
were VEGFR+, with 6 of the 7 (85.71%) patients with 
 CTC2CK+VEGFR+ showing favorable responses, and just 
1 of the 7 (14.29%) patients showing a non-favorable 
response. The remaining 11  CTC2CK+VEGFR− patients 
were identified as responders (p > 0.05) (Fig. 3).
On the other hand, according to RECIST, at 24 weeks 
9 of the 12 (75%) CTC3+ patients showed favora-
ble responses with only 3 of them (25%) developing 
a non-favorable response. According to CyCAR, 5 of 
the 12 (42%) patients were  CTC3CK+VEGFR+ and all of 
them showed a favorable response. However, in the 
 CTC3CK+VEGFR− group (7/12), 4 (57%) were identified as 
responders and three as non-responders (43%), showing 
no statistical differences between the groups (p > 0.05).
Table 2 Dynamic fluctuation of CTCs in patients according to VEGFR status during follow-up
CTCs: circulating tumor cells; CK: cytokeratin; VEGFR: vascular endothelial growth factor receptor; SD: standard deviation; p: p value
CTC1 (baseline) CTC2 (12 weeks) CTC3 (24 weeks) p (CTC1 vs CTC2) p (CTC1 vs CTC3) p (CTC1–CTC3)
Patients with CTCs  (CTCsCK+) N (%) 33 (42.8%) 18 (29%) 12 (18.2%) 0.088 0.005 0.015
Mean number of  CTCsCK+ (SD; 
range)
1.5 (1.5; 0–8) 1.7 (8.1; 0–64) 0.5 (1.5; 0–9) 0.019 0.003
Patients with  CTCsCK+VEGFR+) N (%) 23 (69.7%) 7 (38.9%) 5 (41.7%) 0.102 0.317 0.368
Mean number of  CTCsCK+VEGFR+ 
(SD; range)
1.4 (1.5; 0–5) 0.6 (1.05; 0–3) 0.5 (0.8; 0–2) 0.120 0.317
Fig. 3 Evaluation of FOLFOX–bevacizumab response by RECIST 
and CyCAR criteria together with CTCs VEGFR status. FR favorable 
response, NFR non‑favorable response, w week
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Prognostic significance of CTCs detection
36 of the total 74 patients enrolled in this study died from 
disease progression. Median overall survival for these 36 
patients was 18.3 months, compared to 37.5 months for 
the remaining 38 patients.
In the univariate analysis of the factors associated with 
OS (Table  3), we did not find any positive association 
between RECIST response at 12 weeks and risk of death 
(HR: 0.26, 95% CI 0.06–1.14; p > 0.05). In the same way, 
there was no correlation between CyCAR at 12  weeks 
(CTC2) and risk of death (HR: 1.36; 95% CI 0.62–3.01; 
p > 0.05).
At 24 weeks, we found no positive correlation between 
the risk of death and CyCAR and RECIST criteria (HR: 
0.221; 95% CI 0.22–1.12; p > 0.05 and HR: 0.5; 95% CI 
0.22–1.26; p > 0.05, respectively).
Then, we analyzed the OS in responder and non-
responder patients by RECIST and CyCAR. We observed 
that the median OS in responder vs. non-responder 
patients was 48.6 vs. 14.8  months according to RECIST 
and 55.4 vs. 22.4  months by CyCAR, evaluated at 
24 weeks. In conjunction with these results, the presence 
of CTCs after treatment identified those patients with 
worse OS, which was in concordance with the results 
obtained by RECIST.
In the univariate analyses, metastasis surgery was 
significantly associated with a higher overall survival 
(HR = 0.35; 95% CI 0.15–0.81; p = 0.014). In the same 
way, we found that the presence of synchronous metas-
tasis decreased the OS when compared to the presence 
of metachronous metastasis (HR = 15.89; 95% CI 2.04–
123.35; p = 0.008).
The multivariate analysis included the significant risk 
factors from the univariate analysis. Response assess-
ment at 12  weeks by RECIST, response assessment at 
24 weeks by CyCAR, and synchronous metastasis varia-
bles were independent prognostic factors associated with 
OS (Table 3). According to the PFS, RECIST response at 
12 weeks was the only significantly associated variable in 
the multivariate analysis.
Discussion
RECIST has been adopted as the standard method for 
tumor assessment and helps in clinical decision mak-
ing. Deciding and then monitoring the effectiveness of 
individual therapies in mCRC patients is currently very 
challenging, as a result of the high prevalence of lymph 
abdominal, peritoneal, serous and pleural metastasis, 
which are particularly difficult to evaluate by RECIST 
[16]. In addition, the thresholds (of response or progres-
sion) for predicting differences in survival in treated 
patients probably differ according to the type of treat-
ment and the type of cancer [17]. For example, targeted 
molecules such as anti-VEGF or anti-EGFR often induce 
only small size changes, whereas patient survival is signif-
icantly prolonged. Therefore, specific criteria for certain 
diseases or treatments are necessary, as the current bio-
markers and imaging evaluation options to monitor and 
register treatment clinical responses do not yet allow for 
optimal management of individual patients yet [18].
The hypothesis that CTCs are a fundamental pre-
requisite to metastasis was first proposed in the mid-
nineteenth century (1869) by Thomas Ashworth, an 
Australian pathologist [19]. The characterization of 
CTCs, derived from a ‘simple’ blood test, have the poten-
tial to serve as ‘real-time tumor biopsies’ permitting 
accurate, up-to-date pictures of tumor activity, without 
the need for invasive tissue biopsies. Furthermore, CTCs 
can be analyzed on a serial basis, allowing real-time iden-
tification of emerging treatment ‘resistance profiles’, and 
consequently, being of significant assistance to the radio-
logical assessment of tumor responses [20].
We performed this study in 77 patients with metastatic 
colorectal cancer treated in a homogeneous manner. The 
overall response rate to treatment was 24  months and 
median overall survival was 23.3 months, which did not 
differ from that expected [21]. In our study, we cover 
responses of metastatic colon cancer patients to beva-
cizumab, assessing and comparing CTCs and standard 
evaluation criteria, and we found comparable results to 
other published studies.
In our study, we compared CyCAR to RECIST in the 
same mCRC patient cohort, to determine the specific 
importance of CyCAR. In addition, we analyzed the asso-
ciation between OS and PFS with different clinic-patho-
logical characteristics such as the presence of CTCs, at 
follow-up times.
The correlation between K-RAS tumor status and the 
presence of CTCs was analyzed, finding borderline sig-
nificant association (p = 0.06) between higher percent-
ages of CTC positive patients with K-RAS wild-type 
tumors. Similar results were reported in a recent study 
with 24 metastatic colon cancer patients by Das et  al. 
[22]. In the same way, Buim et al. [23] observed that only 
9 of their 23 CTCs positive patients had K-RAS muta-
tions in their corresponding primary tumors. Our results, 
together with the aforementioned studies, suggest that 
the dissemination of CTCs is an independent process to 
K-RAS status in the primary tumor.
On the other hand, we detected a direct association 
between the presence of CTCs and primary tumor sur-
gery. In fact, most patients undergoing primary tumor 
surgical treatment were positive for the presence of 
CTCs. These results concur with several studies, which 
demonstrated that primary tumor resection can stimulate 
cellular proliferation of residual colorectal tumors [24]. 
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Table 3 Univariate and multivariate Cox regression analysis for overall survival (OS)
Characteristics Univariate analysis Multivariate analysis
Median OS 
(months)
HR 95% CI p HR 95% CI p
All patients 30.3
Age
 < 55 22.4 1.72 0.88–3.37 0.113
 ≥ 55 23.4
Gender
 Male 23.3 0.70 0.36–1.38 0.307
 Female 20
Primary tumor location
 Colon 22.4 0.78 0.39–1.58 0.497
 Rectum 22.85
Primary tumor surgery
 Yes 39.4 0.17 0.08–0.37 < 0.0001 0.37 0.12–1.11 0.075
 No 11.6
Response (12 weeks) (RECIST)
 Favorable 41.6 0.26 0.06–1.14 0.074 0.1 0.02–0.58 0.011*
 Adverse 16.8
Response (24 weeks) (RECIST)
 Favorable 48.6 0.51 0.22–1.20 0.123
 Adverse 14.8
K‑RAS status
 Mutated 36.9 1.95 0.96–3.97 0.064 1.58 0.68–3.68 0.289
 Wild‑type 55.4
Metastasis surgery
 Operated 68.4 0.35 0.15–0.81 0.014 0.39 0.12–1.24 0.111
 Non‑operated 31.1
Synchronous metastasis
 Yes 32.1 15.89 2.04–123.35 0.008 18.33 1.52–221.18 0.022*
 No 68.4
CEA Basal
 High 39.4 1.96 0.84–4.57 0.121
 Standard 55.4
Basal Ca 19.9
 High 22.4 1.68 0.87–3.24 0.123
 Standard 55.4
CTC1
 Favorable 21.6 0.32 0.72–2.79 0.319
 Adverse 23.5
CTC1 VEGFR
 Yes 66.5 0.53 0.25–1.15 0.109
 No 36.9
CTC2
 Favorable 39 1.36 0.62–3.01 0.442
 Adverse 55.4
CTC2 VEGFR
 Yes 36.9 1.44 0.31–6.66 0.640
 No 41.6
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However, other studies demonstrated that primary tumor 
resection improves OS in metastatic colon patients [25]. 
Interestingly, the absence of CTCs in mCRC has been 
also associated with a higher OS in several studies [26].
Additionally, besides analyzing the presence of CTCs, 
we also analyzed their heterogeneous VEGFR expres-
sion. VEGF is the target of bevacizumab, a humanized 
anti-VEGF monoclonal antibody (Bevacizumab; Avas-
tin). This drug has been approved by the FDA in the first 
and second-line colorectal cancer setting, in combina-
tion with chemotherapy. Bevacizumab acts by selectively 
binding circulating VEGF, inhibiting the binding of VEGF 
to its cell surface receptor, and in this way preventing 
its activation. Despite this immobilization of VEGF, we 
found no association between VEGFR status in CTCs 
with the response to treatment, even though we describe 
a no statistically significant reduction in the cell subpop-
ulations of CTC CK+VEGFR+ and a decrease in the number 
of CTC CK+VEGFR+ patients, before and after treatment. 
These results suggest that the treatment could be effec-
tive at removing VEGFR+ tumor cell populations, but 
also selecting VEGFR− populations. Interestingly, Simi-
antonaki et al. [27] demonstrated that negative VEGFR-1 
expression was significantly associated with lymphog-
enous and haematogenous metastases. In the same 
way, Hanrahan et al. [28] found a significant increase of 
VEGFR-1 mRNAs in T3/T4 colorectal carcinomas com-
pared to lymphogenously metastasising tumors, and 
Lebok et al. [29] showed that low VEGFR-1 tumor expres-
sion was associated with lower survival and correlated 
with an advanced disease status in breast cancer. Accord-
ing to these results, we expected  CTCsCK+VEGFR− patients 
to have a worse prognosis; however, we did not observe 
any difference in OS or PFS between patients with 
 CTCsCK+VEGFR+ and  CTCsCK+VEGFR−. In this context, 
Senger et al. [30] demonstrated the existence of autocrine 
VEGF signaling in human tumors that might reflect the 
importance of VEGF for sustaining the self-sufficiency or 
autonomy of tumor cells, especially relevant to aggressive 
cancers and to the biology of cancer stem cells. Autocrine 
VEGF signaling is also closely associated with tumor ded-
ifferentiation and with epithelial–mesenchymal transi-
tion (EMT), which are processes involved in the genesis 
of cancer stem cells. In this context, it has been suggested 
that autocrine signaling blocking by bevacizumab is 
modest and that its action can be improved by combining 
autocrine signaling blocking therapies [31]. These men-
tioned analyses, could explain why we cannot find differ-
ences in the OS and PFS between positive and negative 
VEGFR expression in CTCs.
The principal objective of this study was to compare 
CyCAR with RECIST to predict bevacizumab response. 
In our analysis, we observed no differences between both 
criteria. In fact, we detected similar results when we com-
pared the CyCAR and the RECIST response at 12 weeks. 
We also obtained similar results when analyzing the 
assessment response at 12 (71% vs. 93%) and 24  weeks 
(82% vs. 80%) for CyCAR and RECIST respectively.
Our results suggest that the presence of CTCs at 12 and 
24 weeks can be useful predictive markers, and used as a 
complementary tool with RECIST, even in those patients 
where RECIST can be more difficult to apply.
We also analyzed the predictive role of the presence 
of CTC CK+VEGFR+ to assess the treatment response in 
these patients. However, due to the low number of CTC 
CK+VEGFR+ patients we have not been able to demonstrate 
that the presence of VEGFR in CTCs is a predictive fac-
tor of tumor response to FOLFOX–bevacizumab. How-
ever, it would be important to note that one the principal 
limitation of this study is the methodology used to iso-
late these CTCs, since this isolation is based on the epi-
thelial markers expression, therefore, we could be losing 
an important subpopulation of CTCs, which are under 
EMT process. Recently, Zhang et al. [32], demonstrated 
*: Statistically significant
CTC: circulating tumor cell; OS: overall survival; HR: hazard risk; CI: confidence interval; VEGFR: vascular endothelial growth factor receptor positive; RECIST: Response 
Evaluation Criteria in Solid Tumors; p: p value
Table 3 (continued)
Characteristics Univariate analysis Multivariate analysis
Median OS 
(months)
HR 95% CI p HR 95% CI p
CTC3
 Favorable 55.4 0.52 0.22–1.26 0.149 0.35 0.12–0.99 0.049*
 Adverse 22.4
CTC3 VEGFR
 Yes 22.4 1.04 0.23–4.81 0.958
 No 30.9
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that VEGF expression rate in mesenchymal CTCs was 
significantly higher than that of epithelial CTCs, which 
suggested that VEGF may be correlated with tumor 
malignancy “and probably with the resistance”.
Although these results suggest the value and impor-
tance of CTCs for monitoring treatments, further studies 
are necessary including, not only more patients, but also 
a deeper study about the autocrine and paracrine activ-
ity involved in the activation of VEGF and its role in the 
migration and proliferation of circulating tumor cells.
Conclusion
These results suggest that CyCAR is similar to RECIST 
criteria at evaluating the response in metastatic colorec-
tal carcinoma. Although RECIST is useful for evaluating 
treatment efficacy in clinical trials and practice, it has 
some limitations. This way, we propose the use of CyCAR 
and RECIST combination for a better response predic-
tion of metastatic colorectal carcinoma, in special when 
RECIST is limited.
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